Kereos, Inc
 
 

Product Pipeline - Development
Earlier and More Definitive Diagnosis

KI-0001
MRI agent for tumor detection

Imaging angiogenesis via the avB3 integrin biomarker, KI-0001 can find tumors as small as 1-2 mm in size, while also highlighting actively growing regions in the tumor margin. By monitoring angiogenesis, KI-0001 also offers the opportunity to monitor response to anti-angiogenic therapies.


KI-0001 Tumor Detection Human melanoma in mouse
1.5T MRI

KI-0003
MRI using Flourine-19 technology

Expanding on the Kereos technology platform, the KI-0003 product uses both the avB3 integrin biomarker and Fluorine-19 imaging to detect tumors. Like KI-0001, KI-0003 can detect tumors early in development which should allow for earlier diagnosis and more effective treatment. 19F imaging is the new paradigm of imaging technology and Kereos is on the cutting edge.


KI-1003
Targeted chemotherapeutics for solid tumors

Kereos’ lead cancer therapeutic incorporates the Kereos nanotechnology with a well known peptide. This peptide’s anti-tumor potential has been known for many years. However, this peptide has not been used as a cancer therapeutic due to toxicity.

Kereos’ uses its unique nanotechnology to pinpoint tumors for attack by this peptide while shielding healthy cells. This approach also has the potential to avoid some of the toxic side effects seen in previous cancer therapies.